Mesoblast (MESO) news

Gapack: Trading in shares will remain suspended

Trading in shares of Gapack has remained suspended as of October 5, 2026, with no indication of a near-term resumption. The suspension, initially implemented to allow for a review of the company’s financial disclosures and operational status, continues while regulatory authorities and the company…

Mesoblast gets FDA OK for Ryoncil's new potency assay

Mesoblast Limited (ASX:MSB) has received approval from the U.S. Food and Drug Administration (FDA) for a new potency assay for Ryoncil, its autologous bone marrow-derived stem cell therapy used in the treatment of complex perianal fistulas in patients with Crohn’s disease. The new assay is intended…

MesoBlast Limited - FDA approves new potency assay for commercial ryoncil

MesoBlast Limited has announced that the U.S. Food and Drug Administration (FDA) has approved a new potency assay for the commercial production of Ryoncil, the company’s flagship product. This development follows a Type A meeting with the FDA, during which key aspects were reviewed and validated .…

Mesoblast Limited - Anticipate that we may continue to incur significant losses for foreseeable future

MesoBlast Ltd FY revenue USD 120.3 million

Mesoblast Ltd. reported fiscal year (FY) revenue of USD 120.3 million, reflecting the company’s financial performance during the period. The revenue figure provides insight into the company’s operations and market position, though specific details regarding revenue composition or growth drivers…